Anti-HER3 antibodies or genetic silencing of the HER3 gene reduces colon cancer cell proliferation, migration, and invasion.[33] HRGs and the heterodimer HER3/HER2 mediate the development of resistance to cetuximab in preclinical models. This evidence concerns the gene ERBB2 and colonic neoplasm.